Phibro Animal Health (PAHC) Q3: Strong Earnings & Financials

Font: Financial Modeling Prep  • Aug 27, 2026

Phibro Animal Health (NASDAQ: PAHC) Reports Strong Quarterly Performance and Solid Financials

• Phibro Animal Health (NASDAQ: PAHC) exceeded analyst expectations with strong earnings per share and revenue growth in its latest quarter.
• The company's valuation metrics, including a P/E ratio of 14.15 and a price-to-sales ratio of 0.96, suggest potential investment value.
• Phibro Animal Health demonstrates financial stability with a manageable debt-to-equity ratio of 1.54 and a robust current ratio of 2.96.

Phibro Animal Health (NASDAQ: PAHC) is a leading company that develops and sells a wide range of animal health and mineral nutrition products. It operates globally, providing essential solutions for livestock such as poultry, swine, and cattle. The company functions within the competitive Medical - Products industry, where it has shown consistent financial performance.

On August 26, 2026, Phibro Animal Health reported strong quarterly results. The company announced earnings per share (EPS) of $0.85. This figure surpassed the analyst consensus estimate of $0.71. As highlighted by Zacks Investment Research, this represents a significant 18.06% positive surprise and a substantial increase from the $0.57 EPS reported in the same quarter last year, showcasing robust financial growth.

Phibro Animal Health also delivered impressive revenue figures for the quarter. The company posted revenues of $396.70 million, which exceeded the consensus estimate of $381.18 million. This strong performance marks a 5% increase compared to the prior year, as noted by Business Wire. The revenue beat the Zacks Consensus Estimate by 8.35%, indicating strong market demand for its animal health solutions.

Looking at its valuation, Phibro Animal Health has a trailing price-to-earnings (P/E) ratio of 14.15. The P/E ratio is a key metric that helps investors gauge a company's market value relative to its earnings. A lower P/E can sometimes suggest a stock is undervalued. The company also has a price-to-sales ratio of 0.96 for the same period, providing further investment insights.

The company's financial stability metrics provide further insight into its operational health. Phibro Animal Health holds a debt-to-equity ratio of 1.54, which compares its total debt to its shareholder equity. It also has a robust current ratio of 2.96. This ratio measures a company's ability to pay its short-term obligations with its short-term assets, indicating strong liquidity and financial health.